TACS-CI-IIDDs
What it found
No result yet.
What was tested
Treatment tested
- Neuroelectrical modulation group
Placebo or sham
- Pseudo-neuromodulation group
What it measured
Main measures
Expanded Disability Status Scale, EDSS score
At the 5-day point of treatment and 1 month following the end of treatment
Disability progressionSymbol Digit Modalities Test (SDMT) scale
At the 5-day point of treatment and 1 month following the end of treatment
Thinking and memoryScoring results for tasks 1 and 7 in the Alzheimer disease assessment scale-cog(ADAS-cog)
At the 5-day point of treatment and 1 month following the end of treatment
Thinking and memory
Other measures (6)
Mini-mental State Examination（MMSE）
At the 5-day point of treatment and 1 month following the end of treatment
Thinking and memoryMontreal-Cognitive Assessment（MoCA）
At the 5-day point of treatment and 1 month following the end of treatment
Thinking and memoryStroop Color-Word Test score
At the 5-day point of treatment and 1 month following the end of treatment
Thinking and memoryHamilton Depression Scale，HAMD
At the 5-day point of treatment and 1 month following the end of treatment
Mood and sleepHamilton Anxiety Scale，HAMA
At the 5-day point of treatment and 1 month following the end of treatment
Mood and sleepa subjective questionnaire，adverse effects
Following the first day of treatment，Following the second day of treatment，Following the third day of treatment，Following the fourth day of treatment，Following the fifth day of treatment
Safety
Who could take part
MS (type not specified) · 18 to 60
Inclusion Criteria: * Age: 18-60 years old. * Diagnosis: Patients with neuromyelitis optica spectrum disease, multiple sclerosis and other inflammatory demyelinating diseases of the central nervous system that meet the diagnostic criteria. * Medications have been stable for at least three months. Exclusion Criteria: * Recurrence has been recorded in the past 3 months. * Have a pacemaker or other metal implant in the body. * Impaired skin integrity at the site of electrode placement. * Previous organic brain disease such as epilepsy, hydrocephalus, central nervous system tumors, brain injury, or intracranial infection. * Combined with severe or unstable organic diseases, such as heart, liver and kidney and other organ dysfunction. * Pregnant or lactating women, those who are planning to become pregnant in the near future. * Patient compliance is poor. * In the opinion of the investigator, there is a situation that is not suitable to participate in this study.
As registered. Criteria can change, so ask the trial team or your neurologist.
Contact details on the registryAbout this trial
In the sponsor's words
This study aims to explore the imaging and electrophysiological characteristics of idiopathic inflammatory demyelinating diseases (IIDDs), and their correlation with clinical manifestations. It also evaluates the effectiveness of transcranial electrical stimulation in alleviating clinical symptoms of IIDDs patients, and analyzes the key factors affecting the treatment efficacy. By uncovering the overall and individual characteristics of IIDDs, this study seeks to enhance therapeutic outcomes through personalized neuromodulation programs. The findings will provide a basis for applying non-invasive brain stimulation (NIBS) in IIDDs treatment and offer new ideas for future personalized medicine approaches.
Loading reviews and guidelines…
History
Started
May 2025
Main results due
Oct 2027
Finished
Oct 2027
Assembled by software from public sources and not checked by people. Each record links to its source. Report an error